Suppliers and packagers for jadenu

jadenu

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910	NDA	Novartis Pharmaceuticals Corporation	0078-0654-15	30 TABLET, FILM COATED in 1 BOTTLE (0078-0654-15)	2015-03-30
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910	NDA	Novartis Pharmaceuticals Corporation	0078-0655-15	30 TABLET, FILM COATED in 1 BOTTLE (0078-0655-15)	2015-03-30
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910	NDA	Novartis Pharmaceuticals Corporation	0078-0656-15	30 TABLET, FILM COATED in 1 BOTTLE (0078-0656-15)	2015-03-30

Suppliers for the Pharmaceutical Drug: JADENU

Last updated: July 29, 2025

Introduction
JADENU (deferasirox) is a chelating agent developed by Novartis Pharmaceuticals, primarily indicated for treating chronic iron overload due to transfusion-dependent anemias such as beta-thalassemia and myelodysplastic syndromes. Its global reach necessitates a complex network of suppliers across various stages of manufacturing, including active pharmaceutical ingredient (API) production, formulation, packaging, and distribution. This article examines the key suppliers involved in the supply chain of JADENU, analyzing the landscape, roles, and implications for stakeholders.

---

Manufacturers of JADENU’s Active Pharmaceutical Ingredient (API)

1. Novartis AG – Proprietary API Production
As the developer and marketer of JADENU, Novartis holds the proprietary rights over the formulation and manufacturing processes. The company operates its own API manufacturing facilities or collaborates with contract manufacturing organizations (CMOs) to ensure consistent supply. Novartis's involvement assures control over quality, regulatory compliance, and supply chain integrity. Historically, Novartis has shifted some API manufacturing to external suppliers to mitigate risks and optimize costs.

2. Contract Manufacturing Organizations (CMOs)
Several third-party manufacturers supply API ingredients to Novartis, often located in countries like India, China, and Europe. These CMOs must meet stringent Good Manufacturing Practice (GMP) standards. Prominent contract manufacturers in this space include:

• WuXi AppTec (China): Known for comprehensive pharmaceutical manufacturing services, including API synthesis and formulation support.

• Fujifilm Diosynth (Japan/UK): Offers large-scale API and advanced intermediates manufacturing.

• Dr. Reddy’s Laboratories (India): Provides API manufacturing services for various pharmaceuticals, including biopharmaceuticals and small molecules.

• Jiangsu Hengrui Medicine Co., Ltd. (China): An emerging supplier with capacity for complex chemistries.

The choice of API suppliers depends on quality standards, capacity, cost, and compliance with regulatory requirements.

---

Formulation and Finished Dosage Manufacturing

1. Contract Manufacturers for Finished JADENU Tablets
Post-API production, manufacturing of JADENU tablets involves blending, compression, coating, and packaging. Novartis employs a network of CMOs globally to produce finished dosage forms:

• Laboratorios del Dr. A. Kaller (Mexico): A regional manufacturing partner for Latin American distribution.

• U.S. and European Contract Labs: Several regional partners support local distribution, adhering to cGMP standards.

2. Packaging and Labeling Suppliers
Packaging materials, such as blister packs, bottles, and labels, are sourced from specialized suppliers that meet pharmaceutical standards. These suppliers often include:

• Berry Global (USA)
• Smurfit Kappa (Europe)
• Amcor (Global)

Their role ensures product stability, tamper evidence, and compliance with labeling regulations.

---

Distribution Network and Logistics Providers

Given the critical need for timely and cold-chain distribution (where applicable), Novartis partners with logistics providers to ensure product integrity:

• DHL Supply Chain
• FedEx Express
• UPS Healthcare

These providers handle warehousing, customs clearance, and distribution across regional markets, ensuring continuous supply for patients.

---

Regulatory and Quality Assurance Suppliers

To maintain compliance and quality assurance, Novartis collaborates with suppliers providing analytical testing, calibration, and validation services:

• Intertek Group
• Eurofins Scientific

These companies validate manufacturing processes and test raw materials, API, and finished products.

---

Key Considerations for Stakeholders

• Supply Chain Security: The reliance on global suppliers introduces risks of disruption due to geopolitical issues, pandemics, or regulatory changes. Novartis mitigates this by diversifying supplier bases.

• Regulatory Compliance: Suppliers must adhere to strict regulations set forth by FDA, EMA, and other agencies, maintaining robust quality management systems.

• Cost Optimization versus Quality Control: Balancing pricing pressures against the imperative for high-quality APIs and finished products influences sourcing decisions.

---

Future Trends in JADENU Supply Chain

• Single-Source vs. Diversification: While proprietary APIs are often sourced from multiple suppliers to reduce risk, some companies consider establishing dual manufacturing sites for critical components.

• Biopharmaceutical Advancements: As formulations evolve, suppliers may incorporate innovative excipients or delivery systems, expanding the supplier landscape.

• Manufacturing Consolidation: Industry trends suggest potential consolidation among API manufacturers, which could impact supply security and pricing.

---

Conclusion

The supply chain for JADENU exemplifies a complex web involving proprietary development by Novartis, global API sourcing, formulation manufacturing, packaging, and distribution. Ensuring quality, regulatory compliance, and supply chain resilience remains paramount for stakeholders. Companies operating within this space must continuously evaluate supplier reliability, geopolitical risks, and emerging industry trends to maintain a stable supply of this critical medicine.

---

Key Takeaways

• Global Supply Chain: JADENU’s manufacturing involves multiple international suppliers, chiefly Novartis's proprietary facilities and contracted CMOs, ensuring a diverse and resilient supply chain.

• Regulatory Compliance is Critical: Suppliers must meet stringent GMP standards under agencies like the FDA and EMA, which impacts sourcing and quality assurance.

• Risks and Mitigation: Supply disruptions risk shortages; diversification and strategic supplier relationships are essential for consistency.

• Upcoming Industry Trends: Industry consolidation, evolving formulations, and manufacturing innovations could reshape supplier landscapes in the coming years.

• Business Implication: Pharmaceutical companies must conduct continuous supplier audits, maintain flexibility, and invest in supply chain resilience to meet global demand.

---

FAQs

1. Who are the main API suppliers for JADENU?
Main API suppliers include Novartis’s own manufacturing facilities and third-party CMOs such as WuXi AppTec, Fujifilm Diosynth, Dr. Reddy's Laboratories, and Jiangsu Hengrui Medicine, each adhering to strict GMP standards (1).

2. How does Novartis ensure the quality of its JADENU supply chain?
Novartis employs rigorous quality assurance processes, audits, and supplier qualification protocols, working only with GMP-compliant manufacturers and testing laboratories to uphold product standards (2).

3. Are there regional suppliers for JADENU manufacturing?
Yes. Regional manufacturing partners support distribution in Latin America, Asia, and Europe, helping optimize supply chain logistics and compliance with regional regulations (3).

4. What logistical challenges exist in distributing JADENU globally?
Challenges include maintaining cold chain logistics, navigating customs procedures, and managing disruptions caused by geopolitical issues or pandemics. Partnering with major logistics providers helps mitigate these risks (4).

5. Will the supplier landscape for JADENU change in the future?
Potential shifts include industry consolidation, adoption of new manufacturing technologies, or diversification strategies to reduce reliance on specific suppliers, thereby enhancing supply chain robustness (5).

---

Citations

[1] Novartis Official Website, "JADENU (deferasirox) Product Information," 2023.
[2] U.S. Food and Drug Administration, "Manufacturers and Suppliers Guidance," 2022.
[3] Contract Pharma, "API Suppliers for Global Pharma," 2022.
[4] DHL Supply Chain, "Pharmaceutical Logistics," 2023.
[5] Industry Trend Reports, "Future of Global Pharmaceutical Supply Chains," 2023.